Showing 861-870 of 1046 results for "".
- First Patient Treated in Multicenter Trial Examining Allotex TransForm Allogenic Refractive Lenticules for Treatment of Presbyopiahttps://modernod.com/news/first-patient-treated-in-multicenter-trial-examining-allotex-transform-allogenic-refractive-lenticules-for-treatment-of-presbyopia/2479889/Start-up ophthalmic device company Allotex announced the commencement of a European multicenter trial for its investigational TransForm allogenic refractive lenticules for the treatment of presbyopia. The treatment was performed on Thursday by Arthur Cummings, MB ChB, FCS(SA), MMed(Ophth)
- Oyster Point Pharma Announces Collaboration with Adaptive Phage Therapeutics to Target Ophthalmic Diseaseshttps://modernod.com/news/oyster-point-pharma-announces-collaboration-with-adaptive-phage-therapeutics-to-target-ophthalmic-diseases/2479281/Oyster Point Pharma announced a newly formed research collaboration with Adaptive Phage Therapeutics (APT) to leverage APT’s PhageBank technology for the development of potential treatments for multiple ophthalmic diseases. APT’s PhageBank technology is engi
- Oyster Point Announces Enrollment of First Subject in Phase 3 Clinical Trial of Nasal Spray for Dry Eye Diseasehttps://modernod.com/news/oyster-point-announces-enrollment-of-first-subject-in-phase-3-clinical-trial-of-nasal-spray-for-dry-eye-disease/2476763/Oyster Point Pharma announced enrollment of the first subject in the phase 3 ONSET-2 clinical trial of OC-01 nasal spray for the treatment of the signs and symptoms of dry eye disease. “After successfully compl
- Oyster Point Pharma Submits a Phase 2 Clinical Trial Protocol to Evaluate OC-01 Nasal Spray for Neurotrophic Keratitis (NK)https://modernod.com/news/oyster-point-pharma-submits-a-phase-2-clinical-trial-protocol-to-evaluate-oc-01-nasal-spray-for-neurotrophic-keratitis-nk/2478616/Oyster Point Pharma announced it has submitted to the FDA a protocol to initiate a clinical study in adult patients with neurotrophic keratitis (NK). The submission was made to Oyster Point’s investigational new drug (IND) for OC-01 (varenicline) nasal spray in dry eye disea
- The Vision Council Announces Dates for the 2021 Virtual Executive Summit: January 26–28, 2021https://modernod.com/news/the-vision-council-announces-dates-for-the-2021-virtual-executive-summit-january-26-28-2021/2478440/The Vision Council today announces that the
- Quantel Medical Launches Dry Eye Information Website for Patientshttps://modernod.com/news/quantel-medical-launches-dry-eye-information-website-for-patients/2479085/Quantel Medical has launched
- Hadley Launches New Website For Those Facing Vision Losshttps://modernod.com/news/hadley-launches-new-website-for-those-facing-vision-loss/2478068/In 1920, William Hadley, a Chicago area high school teacher who lost his sight at the age of 55, revolutionized the way adults facing vision loss would learn to read again when he created his Braille by Mail system. One hundre
- West Point Optical Group and Verséa Ophthalmics Announce Partnership Supply Agreement for Biovance and Biovance 3L Ocularhttps://modernod.com/news/west-point-optical-group-and-versea-ophthalmics-announce-partnership-supply-agreement-for-biovance-and-biovance-3l-ocular/2482206/West Point Optical Group (WPOG), which operates 86 Pearle Vision stores, and Verséa Ophthalmics announced that the companies have entered into a partnership supply agreement in which Verséa will be the exclusive provider of its Biovance and Biovance 3L Ocular pro
- Verséa Ophthalmics Commences Phase 1 Launch of Novel Tear-Based Point-of-Care (T-POC) Quantitative Testing Platformhttps://modernod.com/news/versea-ophthalmics-commences-phase-1-launch-of-novel-tear-based-point-of-care-t-poc-quantitative-testing-platform/2481745/Verséa Ophthalmics announced the commencement of initial shipments of its T-POC TOTAL IgE Immunoassay and Lateral Flow Readers. T-POC TOTAL IgE Immunoassay Kit is a new quantitative point-of-care test used in the diagnosis and management o
- Oyster Point Pharma to Present New Scientific Analyses at World Cornea Congress VIIIhttps://modernod.com/news/oyster-point-pharma-to-present-new-scientific-analyses-at-world-cornea-congress-viii/2481117/Oyster Point Pharma announced it will present new scientific analyses at World Cornea Congress VIII, which is taking place in Chicago from September 28-29, 2022. “We look forward to presenting our post-hoc analyses on the clini